A landmark study has revealed that autoantibodies-immune proteins traditionally associated with autoimmune disease-may ...

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), ...

Using genetic screening, scientists have found a new drug combination that works against some treatment-resistant lung, brain ...

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced ...

Lung cancer doesn’t just come from smoking. The amount of ultraprocessed food a person eats and drinks could be connected ...

Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and is often diagnosed at advanced stages, ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

New research identifies NF-kappa-B-activating protein-like (NKAPL) as a potent tumor suppressor in non-small cell lung cancer ...

TEM expands its AI-driven Tempus Next platform into breast cancer, targeting key testing gaps to improve care delivery.